Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 2016

View Archived Issues

GeoVax Labs receives award from NIH for HIV vaccine program for Africa

Takeda initiates first-in-human study of TAK-041

Cancer Genetics offers Ventana PD-L1 assay as complementary diagnostic for Tecentriq

HXP-124 as a novel antifungal agent for the treatment for onychomycosis

Novel ARF6 inhibitors with robust in vivo efficacy

Ampio announces results from phase III PIVOT clinical trial

Galderma Research & Development patents retinoid RORgammaT inverse agonists

Laboratorios del Dr. Esteve discloses dual sigma1 and mu-opioid receptor ligands

PharmNovo describes delta-opioid agonists

Morphic Therapeutic completes series A financing to develop next-generation integrin therapies

Janssen Pharmaceutica develops BACE1 and/or BACE2 inhibitors

Gilead Sciences presents FXR agonists

Regen Biopharma enters deal with Eli lilly

New class of small molecules enhances oncolytic virus replication

Eli Lilly initiates phase I trial of LY-3300054 in advanced refractory solid tumors

PsiOxus, BMS to evaluate enadenotucirev plus nivolumab

Array BioPharma submits NDA for binimetinib for advanced NRAS-mutant melanoma

AstraZeneca and Leo Pharma announce licensing agreements for tralokinumab and brodalumab

Sprint Bioscience partners with Karolinska research team in AML

Takeda Pharmaceuticals begins collaboration with Exosome Diagnostics

Targovax initiates phase Ib/II trial of ONCOS-102 in malignant pleural mesothelioma

GS-9883 found to reduce HIV-1 RNA in clinical trial

Gedeon Richter announces acquisition of Finox

Akers Biosciences completes trial of PIFA/Chlamydia Rapid Assay

Phase II study of Shire's SHP-607 misses primary endpoint

Galmed Pharmaceuticals enters collaboration with Yeda Research and Development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...